HDGFFL2: A Potential Drug Target and Biomarker (G84717)

Target Name: HDGFL2

NCBI ID: G84717

HDGFL2

HDGFFL2: A Potential Drug Target and Biomarker

Hemoglobin (HB) is a protein that is found in red blood cells (RBCs) of humans, responsible for carrying oxygen from the lungs to the rest of the body. The HDGFFL2 gene is a transcript variant of the HB gene that has been shown to be involved in the regulation of HB function and structure. In this article, we will discuss the potential drug target and biomarker properties of HDGFFL2, as well as its potential clinical applications.

TheHDGFFL2 gene is located on chromosome 19 at position 6.2 kb and has a mutation at position -694. The mutation results in the substitution of a thymine (T) for a guanine (G) at position -694, which changes the amino acid sequence from Asp694Glu to Asp694Guan. This substitution has been shown to affect the stability and function of the HDGFFL2 protein.

Studies have shown that the HDGFFL2 protein is involved in the regulation of HB function and structure. It has been shown to play a role in the stability of HB伪2 chain, which is the main component of the hemoglobin molecule. The HDGFFL2 protein has also been shown to interact with the myoglobin protein, which is responsible for the storage of oxygen in muscle cells.

The potential drug target properties of HDGFFL2 are due to its involvement in the regulation of HB function and structure. This is an attractive target for drug development due to the importance of HB in the delivery of oxygen to the body. An imbalance in the levels of HDGFFL2 or HB can lead to the development of various diseases, such as anemia, where the body may not have enough HDGFFL2 to maintain healthy hemoglobin levels.

In addition to its potential drug target properties, HDGFFL2 has also been shown to be a potential biomarker for various diseases. The HDGFFL2 protein has been shown to be involved in the regulation of cellular processes, such as cell growth, apoptosis, and angiogenesis. This suggests that it may be a useful biomarker for the diagnosis and treatment of various diseases.

The potential clinical applications of HDGFFL2 are vast and varied. For example, HDGFFL2 has been shown to be involved in the regulation of cellular processes that are relevant to the development and treatment of various diseases, such as cancer, cardiovascular disease, and neurological disorders. It may also be a useful biomarker for the diagnosis and treatment of these diseases.

In conclusion, HDGFFL2 is a promising drug target and biomarker with potential clinical applications. Its involvement in the regulation of HB function and structure makes it an attractive target for drug development, while its potential as a biomarker for various diseases adds to its utility. Further research is needed to fully understand the role of HDGFFL2 in the regulation of cellular processes and its potential as a drug and biomarker.

Protein Name: HDGF Like 2

Functions: Acts as an epigenetic regulator of myogenesis in cooperation with DPF3a (isoform 2 of DPF3/BAF45C) (PubMed:32459350). Associates with the BAF complex via its interaction with DPF3a and HDGFL2-DPF3a activate myogenic genes by increasing chromatin accessibility through recruitment of SMARCA4/BRG1/BAF190A (ATPase subunit of the BAF complex) to myogenic gene promoters (PubMed:32459350). Promotes the repair of DNA double-strand breaks (DSBs) through the homologous recombination pathway by facilitating the recruitment of the DNA endonuclease RBBP8 to the DSBs (PubMed:26721387). Preferentially binds to chromatin regions marked by H3K9me3, H3K27me3 and H3K36me2 (PubMed:26721387, PubMed:32459350). Involved in cellular growth control, through the regulation of cyclin D1 expression (PubMed:25689719)

The "HDGFL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HDGFL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets